Evidence map›Paper›PMID 38879494›Full record

ArticleClinical proteomics2024

Glial fibrillary acidic protein, neurofilament light, matrix metalloprotease 3 and fatty acid binding protein 4 as non-invasive brain tumor biomarkers.

Atefeh Ghorbani, Miyo K Chatanaka, Lisa M Avery, Mingyue Wang, Jermaine Brown, Rachel Cohen, Taron Gorham, Salvia Misaghian, Nikhil Padmanabhan, Daniel Romero and 12 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical proteomics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Review
  2. Serum Biomarkers in Paediatric Neurosurgery: Traumatic Brain Injury and Beyond.Advances and technical standards in neurosurgery · 2026
    Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Atefeh Ghorbani *Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Canada.
Miyo K Chatanaka *Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Canada.
Lisa M AveryBiostatistics Division, Dalla Lana School of Public Health, University of Toronto, Toronto, Canada.
Mingyue WangMeso Scale Diagnostics, LLC., Rockville, MD, USA.
Jermaine BrownMeso Scale Diagnostics, LLC., Rockville, MD, USA.
Rachel CohenMeso Scale Diagnostics, LLC., Rockville, MD, USA.
Taron GorhamMeso Scale Diagnostics, LLC., Rockville, MD, USA.
Salvia MisaghianMeso Scale Diagnostics, LLC., Rockville, MD, USA.
Nikhil PadmanabhanMeso Scale Diagnostics, LLC., Rockville, MD, USA.
Daniel RomeroMeso Scale Diagnostics, LLC., Rockville, MD, USA.
Martin StengelinMeso Scale Diagnostics, LLC., Rockville, MD, USA.
Anu MathewMeso Scale Diagnostics, LLC., Rockville, MD, USA.
George SigalMeso Scale Diagnostics, LLC., Rockville, MD, USA.
Jacob WohlstadterMeso Scale Diagnostics, LLC., Rockville, MD, USA.
Craig HorbinskiFeinberg School of Medicine, Northwestern Medicine, Malnati Brain Tumor Institute of the Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL, USA.
Katy McCortneyFeinberg School of Medicine, Northwestern Medicine, Malnati Brain Tumor Institute of the Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL, USA.
Wei XuBiostatistics Division, Dalla Lana School of Public Health, University of Toronto, Toronto, Canada.
Gelareh ZadehMacFeeters Hamilton Neuro-Oncology Program, Princess Margaret Cancer Centre, University Health Network and University of Toronto, Toronto, ON, Canada.
Alireza MansouriDepartment of Neurosurgery, Hershey Medical Center, Hershey, PA, USA.
George M YousefDepartment of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Canada.
Eleftherios P DiamandisDepartment of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, Canada. diamandis@lunenfeld.ca.
Ioannis PrassasLaboratory Medicine Program, University Health Network, Toronto, Canada. yprassas@gmail.com.

Funding

STINGing GBM: A First-in- Man Clinical Trial in Surgical Resectable Recurrent GBMP50CA221747 · NCI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI Hui Zhang · 2018 to 2026
$21.4M
Canadian Institutes for Health Research, The Canadian Brain Foundation, Canadian Cancer Society Research Institute CCS707057NCI NIH HHS P50 CA221747SPORE for Translational Approaches to Brain Cancer P50CA221747
6 · The paper itself

Abstract

backgroundGliomas are aggressive malignant tumors, with poor prognosis. There is an unmet need for the discovery of new, non-invasive biomarkers for differential diagnosis, prognosis, and management of brain tumors. Our objective is to validate four plasma biomarkers - glial fibrillary acidic protein (GFAP), neurofilament light (NEFL), matrix metalloprotease 3 (MMP3) and fatty acid binding protein 4 (FABP4) - and compare them with established brain tumor molecular markers and survival.

methodsOur cohort consisted of patients with benign and malignant brain tumors (GBM = 77, Astrocytomas = 26, Oligodendrogliomas = 23, Secondary tumors = 35, Meningiomas = 70, Schwannomas = 15, Pituitary adenomas = 15, Normal individuals = 30). For measurements, we used ultrasensitive electrochemiluminescence multiplexed immunoassays.

resultsHigh plasma GFAP concentration was associated with GBM, low GFAP and high FABP4 were associated with meningiomas, and low GFAP and low FABP4 were associated with astrocytomas and oligodendrogliomas. NEFL was associated with progression of disease. Several prognostic genetic alterations were significantly associated with all plasma biomarker levels. We found no independent associations between plasma GFAP, NEFL, FABP4 and MMP3, and overall survival. The candidate biomarkers could not reliably discriminate GBM from primary or secondary CNS lymphomas.

conclusionsGFAP, NEFL, FABP4 and MMP3 are useful for differential diagnosis and prognosis, and are associated with molecular changes in gliomas.

Indexed as

BiomarkersDifferential diagnosisFatty acid binding protein 4 (FABP4)Glial fibrillary acidic protein (GFAP)GlioblastomaGliomaLiquid biopsyMatrix metalloprotease 3 (MMP3)Multiplexed electrochemiluminescence (ECL)Neurofilament light (NEFL)

Identifiers

PMID38879494
PMCPMC11179213

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.